I. Craig Henderson, MD | Authors

Bisphosphonates: Game Changers?

January 15, 2015

Bisphosphonates or the monoclonal antibody denosumab, have the potential to profoundly affect the entire metastatic process, not just the growth of bone metastases.

Targeted Therapy: A Sea Change in the Treatment of Cancer

November 16, 2012

I see a time in the not too distant future when we’ll define tumors this way. What will our subspecialties be? Rather than a breast clinic or a lung clinic, will we perhaps be attending a “HER2 clinic” or an “mTOR clinic” instead?

Can We Abandon Anthracyclines for Early Breast Cancer Patients?

February 15, 2011

The anthracyclines doxorubicin and epirubicin are among the most effective cytotoxic treatments developed for the treatment of breast cancer.

Pharmacology and Clinical Status of Capecitabine

September 01, 2000

In treating cancer, discovering new ways to use or modify old drugs can sometimes be as valuable as the identification of new drugs. This point is elegantly illustrated in Dr. Schilsky’s article about capecitabine (Xeloda), a prodrug that leads to high intratumoral levels of fluorouracil (5-FU).

Endocrine Therapy for Breast Cancer

April 01, 2000

In an admirably concise fashion, Dr.Pritchard summarizes the results of trials randomizing tens of thousands of women in order to evaluate various types and uses of endocrine treatment over more than 50 years. I would never have predicted these results

Recent Advances in the Treatment of Refractory Advanced Breast Cancer

June 01, 1996

The incidence of breast cancer has risen steadily over the past several decades. Breast cancer is second only to lung cancer as a cause of cancer deaths among women; 46,000 women died of breast cancer in the United States alone in 1995. Despite efforts to improve the survival of women with metastatic breast cancer with currently available chemotherapeutic agents, results remain disappointing. The primary use of such agents continues to be for palliation, not cure.